References of "Beckers, Albert"
     in
Bookmark and Share    
See detailEpidemiology and genetics of pituitary tumors
Beckers, Albert ULg

Scientific conference (2013, February)

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailPrise en charge des prolactinomes
VROONEN, Laurent ULg; Daly, Adrian ULg; Beckers, Albert ULg

in Revue Médicale Suisse (2013), 9

Detailed reference viewed: 7 (3 ULg)
Full Text
See detailThe clinical characteristics of pituitary adenomas (PA) in patients with primary hyperparathyroidism (PHPT) with and without MEN1 mutation
Filipponi, S; Rostomyan, Liliya ULg; VALDES SOCIN, Hernan Gonzalo ULg et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 7 (4 ULg)
Full Text
See detailThe clinical and genetic characteristics of patients with gigantism
Rostomyan, Liliya ULg; Daly, Adrian ULg; Tichomirowa, M et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 39 (5 ULg)
Full Text
Peer Reviewed
See detailSomatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations
Jaffrain-Réa, ML; Rotondi, S; Turchi, A et al

in Endocrine-Related Cancer (2013), 20

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailFamilial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene.
BECKERS, Albert ULg; Aaltonen, Lauri A.; Daly, Adrian ULg et al

in Endocrine Reviews (2013)

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their ... [more ▼]

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their management involves neurosurgery, biological therapies, and radiotherapy. Early diagnosis of pituitary tumors while they are smaller may help increase cure rates. Few genetic predictors of pituitary adenoma development exist. Recent years have seen two separate, complimentary advances in inherited pituitary tumor research. The clinical condition of familial isolated pituitary adenomas (FIPA) has been described, which encompasses the familial occurrence of isolated pituitary adenomas outside of the setting of syndromic conditions like multiple endocrine neoplasia type 1 and Carney complex. FIPA families comprise approximately 2% of pituitary adenomas and represent a clinical entity with homogeneous or heterogeneous pituitary adenoma types occurring within the same kindred. The aryl hydrocarbon receptor interacting protein (AIP) gene has been identified as causing a pituitary adenoma predisposition of variable penetrance that accounts for 20% of FIPA families. Germline AIP mutations have been shown to associate with the occurrence of large pituitary adenomas that occur at a young age, predominantly in children/adolescents and young adults. AIP mutations are usually associated with somatotropinomas, but prolactinomas, nonfunctioning pituitary adenomas, Cushing disease, and other infrequent clinical adenoma types can also occur. Gigantism is a particular feature of AIP mutations and occurs in more than one third of affected somatotropinoma patients. Study of pituitary adenoma patients with AIP mutations has demonstrated that these cases raise clinical challenges to successful treatment. Extensive research on the biology of AIP and new advances in mouse Aip knockout models demonstrate multiple pathways by which AIP may contribute to tumorigenesis. This review assesses the current clinical and therapeutic characteristics of more than 200 FIPA families and addresses research findings among AIP mutation-bearing patients in different populations with pituitary adenomas. [less ▲]

Detailed reference viewed: 41 (22 ULg)
Full Text
Peer Reviewed
See detail2013 European Thyroid Association guidelines for the diagnosis and treatment of TSH-secreting pituitary tumors
Beck-Peccoz, P; Lania, A; Beckers, Albert ULg et al

in European Thyroïd Journal (2013)

Detailed reference viewed: 31 (10 ULg)
Full Text
Peer Reviewed
See detaille syndrome auto-immun thyrogastrique: ses effets sur les micronutriments et la tumorigénèse gastrique.
VALDES SOCIN, Hernan Gonzalo ULg; LUTTERI, Laurence ULg; CAVALIER, Etienne ULg et al

in Revue Médicale de Liège (2013)

Summary : The thyrogastric autoimmune syndrome (TAS) was described in patients in whom the serum cross-reacted both with gastric parietal cells antigens and thyroid antigens. We report two cases ... [more ▼]

Summary : The thyrogastric autoimmune syndrome (TAS) was described in patients in whom the serum cross-reacted both with gastric parietal cells antigens and thyroid antigens. We report two cases illustrating the spectrum of pathogical features of TAS. The first case associates Hashimoto’s thyroiditis and anemia perniciosa,and develops a gastric neuroendocrine tumor during follow up. The second case presents with a Graves’ disease and an autoimmune reversible gastritis, secondary to Helicobacter Pylori. Whereas type III autoimmune polyendocrinopathy is rare, TAS is frequent in our experience. Some 13% (32/240) of patients that we have prospectively followed affected with thyroiditis have also autoimmune gastritis. Helicobacter pylori is clearly implicated in 16% of autoimmune gastritis cases. Infection, malabsorption and gastritis are potentially reversible after bacterial eradication treatment. In the other 84% of gastritis patients, no histological or serological proof of Helicobacter pylori is found. Gastric autoimmunity is then irreversible, leading to gastric severe atrophy, hypochlorhydria and hypergastrinemia. Hypergastrinemia stimulates enterochromaffin cell hyperplasia, possibly progressing c to neuroendocrine tumors. We propose a diagnostic approach to improve the characterization of TAS. We review the literature on the subject and discuss some interesting animal models of infectious gastric autoimmunity [less ▲]

Detailed reference viewed: 36 (11 ULg)
Full Text
Peer Reviewed
See detailHigher risk of death among MEN1 patients with mutations in the JunD interacting domain. A Groupe d'étude des Tumeurs Endocrines (GTE) cohort study
Thevenon, Julien; Bourredjem, Abderrahmane; Faivre, Laurence et al

in Human Molecular Genetics (2013)

BackgroundMultiple Endocrine Neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors ... [more ▼]

BackgroundMultiple Endocrine Neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities.MethodsWe report on a cohort of MEN1 patients from the Groupe d'etude des Tumeurs Endocrines. Patients with a molecular diagnosis and a clinical follow-up, totalling 262 families and 806 patients were included. Associations between mutation type, location or interacting factors of the MENIN protein and death as well as the occurrence of MEN1-related tumors were tested using a frailty Cox model to adjust for potential heterogeneity across families.ResultsAccounting for the heterogeneity across families, the overall risk of death was significantly higher when mutations affected the JunD interacting domain (adjusted HR=1.88: 95%-CI=1.15- 3.07). Patients had a higher risk of death from cancers of the MEN1 spectrum (HR=2.34; 95%-CI=1.23- 4.43).ConclusionThis genotype-phenotype correlation study confirmed the lack of direct genotype-phenotype correlations. However, patients with mutations affecting the JunD interacting domain had a higher risk of death secondary to a MEN1 tumor and should thus be considered for surgical indications, genetic counseling and follow-up. [less ▲]

Detailed reference viewed: 28 (11 ULg)
Full Text
See detailFamilial Pituitary Adenomas : An overview
Vasilev, V; Daly, Adrian ULg; Beckers, Albert ULg

in Hayat, MA (Ed.) Tumors of the Central nervous system (2013)

Detailed reference viewed: 49 (18 ULg)
Full Text
See detailThe Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas
Jaffrain Rea, ML; Beckers, Albert ULg

in Hayat, MA (Ed.) Tumors of the Central nervous system (2013)

Detailed reference viewed: 21 (9 ULg)
Full Text
Peer Reviewed
See detailGenetic analysis in young patients with sporadic pituitary macroadenomas:Beside AIP don't forget MEN1 genetic analysis.
Cuny, Thomas; Pertuit, Morgane; Sahnoun-Fathallah, Mouna et al

in European Journal of Endocrinology (2013)

CONTEXT: germline mutations in the AIP gene have been identified in young patients (age </= 30 years old) with sporadic pituitary macroadenomas. Otherwise, there are few data concerning the prevalence of ... [more ▼]

CONTEXT: germline mutations in the AIP gene have been identified in young patients (age </= 30 years old) with sporadic pituitary macroadenomas. Otherwise, there are few data concerning the prevalence of MEN1 mutations in such population. OBJECTIVE: We assessed the prevalence of both AIP and MEN1 genetic abnormalities (mutations and large gene deletions) in young patients (age </= 30 years old) diagnosed with sporadic and isolated macroadenoma, without hypercalcemia and/or MEN1-associated lesions. DESIGN: The entire coding sequences of AIP and MEN1 were screened for mutations. In cases of negative sequencing screening, multiplex ligation-dependent probe amplification was performed for the detection of large genetic deletions. PATIENTS AND SETTINGS: 174 patients from Endocrinology Departments of 15 French University Hospital Centers were eligible for this study. RESULTS: 21/174(12%) patients had AIP (n=15, 8.6%) or MEN1 (n=6, 3.4%) mutations. In pediatric patients (age </= 18 years old), AIP/MEN1 mutation frequency reached nearly 22% (n=10/46). AIPmut and MEN1mut were respectively identified in 8/79 (10.1%) and 1/79 (1.2%) somatotropinoma patients; they each accounted for 4/74 (5.4%) prolactinoma patients with mutations. Half of patients (n=3/6) with gigantism displayed mutations in AIP. Interestingly, 4/12 (33%) patients with non-secreting adenomas bore either AIP or MEN1 mutations, whereas none of the 8 corticotroph-adenomas and a single thyrotropinoma case had mutations. No large gene deletions were observed in sequencing-negative patients. CONCLUSION: mutations in MEN1 can be of significance in young patients with sporadic isolated pituitary macroadenomas, particularly prolactinomas, and together with AIP, we suggest genetic analysis of MEN1 in such population. [less ▲]

Detailed reference viewed: 37 (3 ULg)
Full Text
See detailA prospective study of cardiac valvular status in patients treated with cabergoline for endocrine disease
VROONEN, Laurent ULg; LANCELLOTTI, Patrizio ULg; Tome, M et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 28 (4 ULg)
Full Text
See detailThe role of tyrosin kinase inhibitors in a MEN2B patient with metastatic medullary thyroid carcinoma
Tome, M; Tomas, M-H; VROONEN, Laurent ULg et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 26 (2 ULg)
Full Text
Peer Reviewed
See detailMalabsorption des hormones thyroïdiennes... ou simple manque de compliance ?
Benoit, Arnaud ULg; BOUQUEGNEAU, Antoine ULg; PETROSSIANS, Patrick ULg et al

in Revue Médicale de Liège (2013), 68(3), 118-121

Detailed reference viewed: 41 (1 ULg)
See detailRadiotherapy : controversy
Beckers, Albert ULg

Scientific conference (2012, November)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailExpression et localisation spatio-temporelle de KISS1 et de son récepteur KISSR dans le placenta normal et pathologique.
VALDES SOCIN, Hernan Gonzalo ULg; Munaut, Carine ULg; CHAVEZ, Viviana ULg et al

Poster (2012, October)

Objectif : Etudier l’expression de KISS1 (métastatine) et de son récepteur KISS1R lors de la grossesse normale et pathologique. Matériels et méthodes : Nous avons étudié la localisation de KISS1 et KISS1R ... [more ▼]

Objectif : Etudier l’expression de KISS1 (métastatine) et de son récepteur KISS1R lors de la grossesse normale et pathologique. Matériels et méthodes : Nous avons étudié la localisation de KISS1 et KISS1R par immunohistochimie dans des placentas normaux (1 er et 3 ème trimestre). Par RT-PCR quantitative, nous avons évalué le niveau d’expression des ARNm dans les placentas et les lits placentaires correspondants. Les niveaux d’expression de ARNm ont été comparés entre les grossesses normales (GN, n=13) et les grossesses spathologiques Prééclampsiques -PE-, n=17 et retard de croissance intrautérine -RCIU-, n=9). Résultats : Au premier trimestre des GN, KISS1 est majoritairement localisé dans les syncitiotrophoblastes, alors que KISS1R est détecté dans le mesenchyme villositaire. Au cours du troisième trimestre, KISS1 est uniquement localisé dans le syncitiotrophoblaste au contact avec la décidue et dans le mésenchyme villositaire et KISS1R est détecté dans le trophoblaste extra-villeux ainsi que dans quelques cellules de la décidue. Les analyses par RT-PCR mettent en évidence une expression plus importante des ARNm de KISS1 (p<0,001) et de KISS1R (p=0.039) dans les placentas (GN,PE et RCIU) par rapport aux lits placentaires correspondants. Les niveaux d’expression de KISS1 et KISS1R ne sont pas, cependant, significativement modulés dans les grossesses pathologiques. Conclusions : Par immunohistochimie, nos résultats indiquent une expression spatiotemporelle différente pour KISS1 et KISS1R entre le 1 er et 3 ème trimestre des grossesses normales. Nous n’avons pas mis en évidence de modulation de l’expression des ARNm dans les grossesses pathologiques. [less ▲]

Detailed reference viewed: 34 (8 ULg)
See detailFamilial Pituitary Syndromes
Beckers, Albert ULg

Scientific conference (2012, October)

Detailed reference viewed: 6 (3 ULg)
See detailFamilial Isolated Pituitary Adenomas
Beckers, Albert ULg

Scientific conference (2012, October)

Detailed reference viewed: 4 (2 ULg)